Haemorrhagic cystitis (HC) is a distinct clinical disorder of multiple aetiologies. It is characterized by painful haematuria due to haemorrhagic inflammation of the urinary bladder mucosa. In allogeneic haematopoietic stem cell transplantation (HSCT), HC occurring before engraftment is mostly transient and self-limiting, whereas that after engraftment is severe and sometimes lifethreatening. Pre-and post-engraftment HC represent distinct disorders with different aetiologies and treatment implications. Recent data suggest that reactivation of the polyoma BK virus (BKV) plays a pivotal role in postengraftment HC. Urotoxicity of the conditioning regimen and alloimmune reaction accompanying graft-versus-host disease (GVHD) upon engraftment are also important pathogenetic factors. Based on data from BKV studies, we propose that HC may be divided into three phases. In the first phase, the conditioning regimen damages uroepithelial cells, providing a milieu for BKV replication. In the second phase, unchecked uroepithelial BKV replication leads to BK viruria. In the last phase after engraftment, alloimmunity against BKV-infected uroepithelial cells leads to HC. The quinolone antibiotics suppress BKV replication in vivo and in vitro, suggesting that their prophylactic use may prevent the occurrence of HC. Bone Marrow Transplantation (2005) 36, 929-937.
stem cell transplantation
Haemorrhagic cystitis (HC) is characterized by painful haematuria due to haemorrhagic inflammation of the urinary bladder mucosa. It is a distinct clinical disease that has been associated with various predisposing factors ( Table 1) . 1 In particular, HC is linked to direct bladder mucosal injury caused by irradiation and chemotherapy during treatment for cancers and autoimmune diseases. It is also recognized as an important complication after haematopoietic stem cell transplantation (HSCT). The diagnosis of HC is based on the clinical history, physical examination and the exclusion of alternative causes of painful haematuria (Table 2 ). Its manifestations vary from microscopic haematuria (grade I) to severe bladder haemorrhage leading to clot retention and urinary tract obstruction (grade IV) ( Table 3) . 2 Cystoscopic examination reveals focal or diffuse haemorrhagic and inflammatory changes of the urinary bladder mucosa. 3 The pathogenesis leading to HC has not been elucidated. This is especially true for HC that occurs after HSCT, in which prior chemo-irradiation, cytopenia, viral infections due to immunosuppression and alloimmune reactions may all be contributory. Of these, reactivation of the polyoma BK virus (BKV) during HSCT is the commonest and most consistent risk factor for HC, as the virus is almost invariably present in the urine of patients with this disorder. However, the exact pathogenetic link between BKV and HC remains enigmatic. As a result, there is currently no effective prophylaxis or treatment for this disease.
In this article, we will review data from recent studies that provide evidence linking BKV, chemotherapy/irradiation and immunoreconstitution to HC post-HSCT. A pathogenetic model and its implications on the clinical management of HC will be discussed.
HC post-HSCT
Based on the temporal relationship to donor stem cell engraftment, HC can be divided into pre-and postengraftment subtypes, 4 each with different clinicopathological characteristics and prognosis (Table 4) . Pre-engraftment HC is mainly related to the uroepithelial toxicity resulting from chemotherapy/irradiation in the conditioning regimen. Cyclophosphamide, commonly used in conditioning, is well known to be associated with HC, owing to its conversion to acrolein that is highly toxic to the uroepithelium. Cyclophosphamide-related HC is early in onset and occurs pre-engraftment. It typically subsides spontaneously as the toxic effects of cyclophosphamide wear off. Furthermore, cyclophosphamide-related HC may be preventable by the use of 2-mercaptoethane sulphonate (MESNA). Early studies had compared the efficacy of MESNA with that of forced hydration and shown that the latter alone could also be used as a cost-effective protection against cyclophosphamide-induced HC. 5 Other risk factors of pre-engraftment HC include the use of busulphan in the conditioning regimen, 6 and previous pelvic irradiation. 7 Preengraftment HC is usually mild and self-limiting, posing no serious threats to patients in the early stages of HSCT.
On the contrary, post-engraftment HC is a major complication and a common cause of prolonged hospitalization after HSCT. Generally, it occurs about a month after neutrophil engraftment and may last from 1 week to more than 4 months. 3 A number of retrospective studies have examined the risk factors associated with the occurrence and severity of post-engraftment HC (Table 5) . These studies were different in their HC definition and HSCT protocols, precluding a direct comparison of the effects of these risk factors on the incidence and severity of HC. Nonetheless, the use of busulfan 3, 8 and intensive myeloablative conditioning regimens, 9 allogeneic stem cell source, 10 transplantation from matched unrelated donors 11 and the occurrence of graft-versus-host disease (GVHD) 3, 8 have been generally associated with increased risks of postengraftment HC. The presence of multiple risk factors implies that HC post-HSCT is likely to be multifactorial. In addition, the frequent identification of viral particles from the urine of patients, BKV being the most consistent one, suggests that viral infection may play a pathogenetic role.
Polyoma BKV
Human polyoma BKV (Polyomavirus hominis 1) belongs to the genus Polyomaviridae, which are nonenveloped DNA viruses containing circular double-stranded DNA of about 5 kb in size. It was first identified in 1970 from the urine of a renal allograft recipient named BK, who developed ureteric stenosis. 12 This virus is ubiquitous and more than 80% of the adult population has been exposed to it. The BKV virology, infectious cycles, route of transmission and associated clinical diseases have been extensively reviewed recently. [13] [14] [15] Primary BKV infection is mostly asymptomatic. After primary infection, the virus remains dormant in the urinary tract (including the kidney and bladder uroepithelium), lymphoid tissues and circulating leucocytes. BKV has been associated with various human diseases, including neoplastic transformation, 16 pneumonitis, 17 graft nephropathy in renal allograft transplantation 18 and HC in HSCT. 19 In most cases, the association is based on the presence of the virus in pathological specimens. The putative mechanisms by which BKV leads to these disorders have not been elucidated.
Polyoma BKV genotype
Previous studies have suggested that the outcome of BKV infection may be related to virulence determined by the viral genotype. The BKV genome comprises three regions: the noncoding control region (NCCR) containing the origin of replication, the promoter and enhancer regions; the early structural region encoding the early protein (large and small T-antigens); and the late structural region encoding the agnoprotein and the viral capsid proteins 20 BKV exhibits genetic variation over the NCCR and can be classified into archetype and rearranged forms. 21 Archetype BKV is characterized by a linear NCCR without tandem repeats, whereas the rearranged form exhibits duplication and deletion in NCCR. Base mutations in the NCCR had been postulated to enhance viral replication and hence virulence in HSCT patients. 22 However, other studies 23, 24 showed that most cases of BKV isolated from the urine of HSCT patients with severe HC belonged to the archetype and mutations at NCCR could not be identified. Therefore, there is presently no consistent evidence that mutations of BKV genome may determine its virulence in HC.
Reactivation or transmission of BKV during HSCT
It is widely believed that BKV infection, especially in immunocompromised patients, results from reactivation of the latent virus from dormant sites. However, BKV DNA has also been identified in circulating leucocytes and bone marrow cells of healthy donors, 23, 25 raising the possibility that the virus may be transmitted during blood product transfusion and HSCT. To address the issue of BKV transmission during HSCT, the virus of donor origin has to be distinguished from that of the recipient. A recent study of BKV-related HC post-HSCT examined the NCCR genotypes of BKV from both donors and patients. In eight patients who developed severe post-engraftment HC, BKV of both the donors and recipients belonged to the archetype, 23 making it difficult to ascertain if transmission of donor BKV might be involved. Therefore, the proposition that BKV might be transmissible during HSCT remains to be examined.
BKV and HC
The link between BKV and HC was first suggested in 1976 when papovavirus-like particles were found in the urine of patients with HC. [13] [14] [15] After 10 years, using enzyme-linked immunosorbent assay and Southern blotting, BK viruria was found to be associated with prolonged late-onset HC in HSCT patients. 13 Since then, the link between BKV and HC has been extensively reported, based on the detection of BK viruria with electron microscopy, cytology and amplification of viral DNA by the polymerase chain reaction (PCR). However, given the fact that asymptomatic urinary shedding of BKV occurs frequently in normal individuals and immunocompromised patients, it was not clear if the presence of BKV in HSCT patients with HC was of causal significance, or represented merely a coincidental nonspecific viral reactivation as a result of immunosuppression.
In order to establish a causal link between BKV and HC, at least the following conditions will have to be fulfilled:
(1) BKV viral load should be quantitatively correlated with the occurrence of HC; (2) an increase in BKV load should precede the onset of clinical disease; (3) reduction or abolition of BKV replication should result in a reduced occurrence or severity of the disease.
In the following sections, evidence supporting a causal link between BKV and HC post-HSCT along these lines is provided.
BKV viral load correlates with the occurrence of HC post-HSCT Previous studies of HC post-HSCT, employing PCR, electron microscopy or viral culture, have shown a consistent qualitative association between BK viruria and HC. 3, [13] [14] [15] These studies were limited by the fact that BK viruria could also be demonstrated in a significant proportion of asymptomatic individuals without HC. If BKV was of causative significance, it might be expected that in clinical disease, the BK viruria load would be much higher than that in asymptomatic viruria. With competitive PCR targeting the coding region of the large T-antigen, Azzi et al 26 showed that patients with clinical HC excreted much larger amounts of BKV. Leung et al, 27 using realtime quantitative PCR targeting the BKV VP1 gene (Figure 1 ), also showed that significantly higher BK viruria occurred in HC patients. In patients without HC, the maximum BK viruria during HSCT was about 10 4 -10 5 copies/ml. However, in patients who developed HC, the maximum BK viruria might be as high as 10 8 -10 10 copies/ml. Patients who excreted more than 10 10 BKV copies/day (or about 10 7 BKV copies/ml) were significantly more likely to develop HC as compared with those who excreted less (Figure 2 ). Furthermore, BK viraemia has also been correlated quantitatively with post-engraftment HC. Patients with plasma BKV greater than 10 4 copies/ml appeared to be at higher risk of HC. 28 
Significant increases in BK viruria precede clinical HC post-HSCT
Prospective studies have shown that BK viruria in patients with HC is distinctive not only in its large amounts but also in its pattern. In a cohort of 68 patients undergoing allogeneic HSCT who were studied quantitatively for BK viruria, two patterns of viruria were observed. In the first group of about half the patients, a significant (43 log) peaking of BK viruria occurred at about 2-3 weeks after HSCT. In the second group, a persistent low-level BK viruria without peaking occurred. Interestingly, all patients who developed HC had a peaking in BK viruria, which invariably preceded the onset of haematuria by a median of 29 (2-118) days. Moreover, at the time of haematuria, the BK viruria was already on the decline or had reached baseline levels ( Figure 3 ). 29 Finally, in patients showing low-level BK viruria without peaking, none developed HC. Erard et al 30 recently demonstrated that BK viraemia preceded post engraftment HC by a median of 10 days, further supporting a causal relationship between BKV infection and HC. These results implied that significant BK viruria was a prerequisite for HC. However, as clinical haematuria lagged temporally behind peak BK viruria, a direct viral cytopathic effect leading to the destruction of uroepithelium was unlikely to be the main pathogenetic mechanism.
Reduction of BKV infection may result in a reduced occurrence/severity of HC post-HSCT To date, clinical strategies to decrease the incidence of HC have not been successful. Although HC may be related to the urotoxicity of chemotherapy and irradiation, a reduction of the intensity of the conditioning regimen has not led to a decrease in HC. Yamamoto clinically relevant, as the urinary levels of ciprofloxacin in these patients were comparable to the in vitro concentration needed to suppress BKV replication. Furthermore, none of the patients who had significant suppression of BK viruria developed HC. Although these results have to be validated by the study of more patients in randomized trials, they do support the premise that reduction of BKV may ameliorate or prevent HC.
Alloimmune aetiology of HC
The observation that not all patients with BK viruria develop HC suggests that other pathogenetic factors may be involved. A common clinical experience is that severe post-engraftment HC is very rare among patients who undergo autologous as compared with allogeneic HSCT, even though similar myeloablative conditioning regimens are used. Therefore, the alloimmune reactions after allogeneic HSCT are an important contributing factor. In further support of the immune aetiology of HC are the association between HC and acute GVHD, 3, 8, 33 and the anecdotal reports that HC in patients infected with the human immunodeficiency virus often follows the increase in CD4 þ lymphocyte count after anti-retroviral therapy. 34, 35 In a prospective analysis of a cohort of patients undergoing autologous HSCT, both the level and the percentage of patients showing significant peaking in BK viruria were similar to those of allogeneic HSCT recipients. 36 However, HC developed only after allogeneic and not autologous HSCT. This observation supports the proposition that while BKV is a prerequisite for the development of HC, the alloimmune reactions upon reconstitution of donor haematopoiesis may also contribute to the pathogenesis of HC.
HC -a changing paradigm
We propose that the pathogenesis of post-engraftment HC may be divided into three phases (Figure 4 ). In the first phase, during the conditioning regimen, the use of chemotherapy/irradiation damages the uroepithelium. The subsequent uroepithelial regeneration provides an appropriate cellular milieu for BK viral replication. 13 The immunosuppressive effect of the conditioning regimen also decreases BKV-specific cellular immunity. These combine to provide suitable conditions for BK viral replication. During the second phase, unchecked BK viral replication leads to cytopathic effects, resulting in shedding of BKV in the urine, accounting for the clinical observation of a significant rise of BK viruria. In the final phase, haematopoietic reconstitution occurs subsequent to engraftment of donor haematopoietic stem cells. This leads to the return of anti-BKV immunity from donor lymphoid cells. These donor immunocompetent cells mount an immunological reaction against viral antigens expressed on the uroepithelium. 37, 38 This immune attack, which may or may not be part of a more generalized GVHD, causes extensive mucosal damage and haemorrhage characteristic of severe HC. This model is compatible with the concept of immunorestitution diseases, in which an acute symptomatic deterioration of a pre-existing infection is temporally linked to the recovery of the immune system. 39 Such a model may provide a theoretical framework for the formulation and testing of strategies in the prevention and treatment of HC.
Alternative causes of HC post-HSCT
Besides BKV, other viruses have been associated with the occurrence of HC. In paediatric patients, adenovirus (Ad) is a distinct cause of acute HC. Interestingly, various studies from the Japanese population showed that Ad appeared to be the predominant infective cause of HC post-HSCT. 9, 40, 41 However, the link between Ad and HC in these studies was based largely on the presence of the virus in clinical specimens, and concomitant BKV infection had not been investigated. 40, 41 Prospective quantification of BKV and Ad has been performed in a study of adult patients with HC. While BKV is significantly associated with HC, no relationship between reactivation of Ad and HC could be demonstrated. 27 Anecdotal reports have also found cytomegalovirus (CMV) in the urine of patients with HC. 42, 43 A link has also been proposed between BKV and CMV reactivation in HSCT patients. In fact, urinary BKV excretion may precede that of CMV, due to heterologous transcriptional transactivation of the CMV major IE promoter by the BKV large T antigen. 44 Prospective studies will be needed to quantify the CMV and BKV urinary loads in order to delineate their roles and temporal relationship during HSCT.
Prophylaxis for HC post-HSCT
Pre-engraftment HC can be prevented to some extent by the use of MESNA and/or hyper-hydration in patients receiving conditioning regimens containing cyclophosphamide. However, effective prophylaxis against post-engraftment HC has not been defined. As BKV plays a key role in the pathogenesis of HC, anti-BKV treatment might be expected to be useful. The purine analogue cidofovir is able to inhibit BKV replication both in vitro and in vivo. 29 However, it is myelotoxic and nephrotoxic, limiting its prophylatic use in HSCT. Preliminary data suggest that quinolone antibiotics may suppress BKV replication. 29 As the quinolone antibiotics are not myelotoxic, and most HSCT patients will in any case receive an antibiotic prophylaxis, the potential use of quinolones to prevent BKV reactivation becomes an attractive option. Of the two quinolone antibiotics tested, levofloxacin appeared to show more pronounced in vitro anti-BKV activity than ciprofloxacin. 29 Based on these results, we recommend that in patients who are at risk of post-HSCT HC (Table 5) , quinolone antibiotics should be used for both their antibacterial and anti-BKV effects from the commencement of conditioning to up to at least five weeks (when most BK viruria peaks occur) post-HSCT. It must be noted that the quinolones are not in the strictest sense antiviral agents. Besides, their very modest anti-BKV activity suggests that the quinolones may better serve as a prophylaxis instead of a treatment for an established BKV-related HC. Further randomized studies are needed to validate if the prophylactic use of quinolones may suppress BKV replication and hence HC. Finally, retinoic acid derivatives, including nalidixic acid, have also been shown to inhibit BKV activity in vitro. 31, 32 Whether these agents can likewise reduce BKV replication in HSCT patients at a clinically relevant dosage and hence prevent the occurrence of HC would have to be further investigated.
Treatment of HC post-HSCT
The lack of a unifying pathogenetic mechanism for HC has hampered the design of effective therapeutic strategies. Treatment recommendations are often based on experience from case or series studies (Table 6) .
We recommend that patients who present with painful haematuria post-HSCT should be investigated to rule out alternative diagnoses. The investigations should include urine microscopy, microbiological cultures and cytology; platelet count and coagulation profile; and radiologic investigations to rule out urinary calculi and bladder neoplasms. Patients with urinary symptoms can be treated with phenazopyridine, which exerts a topical analgesic effect on the urinary tract mucosa. Severe painful haematuria can be relieved by systemic opioid analgesia. Microscopic haematuria (grade I) can be treated expectantly. Gross haematuria (grade II) can be treated by oral oestrogens 45 and bladder irrigation to ameliorate symptoms and to prevent obstruction by blood clots. Urologists should be consulted for patients with severe (4grade II) or persistent haematuria (grade II but 47 days, despite bladder irrigation) for the consideration of cystoscopic examination and cauterization. Alum or formalin instillation should also be considered in severe cases. Potential aluminium toxicity and long-term complications of formalin instillation, which include fibrosis of bladder and urinary frequency and/or incontinence, vesico-ureteric reflux and obstruction, should be explained to patients before treatment. 46 Cystectomy with urinary diversion or vesical artery embolization is reserved for refractory and life-threatening cases. [47] [48] [49] [50] In all patients with severe HC (Xgrade 2), correction of thrombocytopenia and coagulopathy can alleviate the severity of haematuria. Prevention of complications arising from prolonged immobilization and hospital stays, as well as psychological support from medical and nursing personnel, will be valuable to patients who have to endure the frustrating and demoralizing experience of protracted bladder catheterization.
In addition to conventional therapy, other approaches have been adopted (Table 7) . Intravenous and intravesical cidofovir have been used in the treatment of HC, based on Table 6 Conventional treatment options for haemorrhagic cystitis 53 replication. However, as BKV replication has already decreased to low levels when HC occurs, and Ad replication has not been consistently identified, the efficacy of antiviral agents in the treatment of established HC needs to be further investigated. Factors VIIa and XIII have also been used in severe HC, [55] [56] [57] by virtue of their procoagulation effects in the bleeding mucosa, but more data will be needed to support their general use in HC. The involvement of alloimmunity in the pathogenesis of HC post-HSCT suggests that immunosuppressive therapy may also be considered in the treatment protocols. This will have to be confirmed with proper randomized studies.
Conclusion
The pathogenesis of post-engraftment HC after HSCT represents an interplay between uroepithelial damage by chemotherapy/irradiation, polyoma BKV infection and alloimmune reactions from donor lymphocytes targeting the recipient uroepithelial cells. Such a model sets a new paradigm for HC, and generates interesting hypotheses on the prevention and treatment of the disorder.
